BR0313293A - Compostos orgânicos - Google Patents
Compostos orgânicosInfo
- Publication number
- BR0313293A BR0313293A BR0313293-5A BR0313293A BR0313293A BR 0313293 A BR0313293 A BR 0313293A BR 0313293 A BR0313293 A BR 0313293A BR 0313293 A BR0313293 A BR 0313293A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- formula
- employed
- treatment
- hypertension
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010020772 Hypertension Diseases 0.000 abstract 2
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 1
- 102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000019025 Hypokalemia Diseases 0.000 abstract 1
- 101150053185 P450 gene Proteins 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000002831 pharmacologic agent Substances 0.000 abstract 1
- 201000009661 posterior myocardial infarction Diseases 0.000 abstract 1
- 208000024896 potassium deficiency disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000007634 remodeling Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40169302P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008720 WO2004014914A1 (en) | 2002-08-07 | 2003-08-06 | Organic compounds as agents for the treatment of aldosterone mediated conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313293A true BR0313293A (pt) | 2005-06-14 |
Family
ID=31715720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313293-5A BR0313293A (pt) | 2002-08-07 | 2003-08-06 | Compostos orgânicos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7732603B2 (enExample) |
| EP (1) | EP1537114B8 (enExample) |
| JP (1) | JP4533139B2 (enExample) |
| CN (1) | CN100404535C (enExample) |
| AT (1) | ATE335744T1 (enExample) |
| AU (1) | AU2003253387A1 (enExample) |
| BR (1) | BR0313293A (enExample) |
| CA (1) | CA2494636A1 (enExample) |
| CY (1) | CY1106217T1 (enExample) |
| DE (1) | DE60307483T2 (enExample) |
| DK (1) | DK1537114T3 (enExample) |
| ES (1) | ES2270143T3 (enExample) |
| PT (1) | PT1537114E (enExample) |
| WO (1) | WO2004014914A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612088B2 (en) * | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| WO2006005726A2 (en) * | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200813071A (en) | 2006-04-12 | 2008-03-16 | Speedel Experimenta Ag | Spiro-imidazo compounds |
| EP2029604A2 (en) * | 2006-05-26 | 2009-03-04 | Novartis AG | Aldosterone synthase and/or 11beta-hydroxylase inhibitors |
| EP2057163A1 (en) * | 2006-08-25 | 2009-05-13 | Novartis AG | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| RU2009127842A (ru) * | 2006-12-22 | 2011-01-27 | Актелион Фармасьютиклз Лтд (Ch) | ПРОИЗВОДНЫЕ 5,6,7,8-ТЕТРАГИДРОИМИДАЗО[1.5-а]ПИРАЗИНА |
| US8859538B2 (en) * | 2007-06-21 | 2014-10-14 | Cara Therapeutics, Inc. | Uses of substituted imidazoheterocycles |
| WO2008157751A2 (en) * | 2007-06-21 | 2008-12-24 | Cara Therapeutics, Inc. | Substituted imidazoheterocycles |
| US20110105514A1 (en) * | 2008-06-25 | 2011-05-05 | Hamed Aissaoui | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| JP5420761B2 (ja) | 2009-05-28 | 2014-02-19 | ノバルティス アーゲー | ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体 |
| KR20120041702A (ko) | 2009-05-28 | 2012-05-02 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| HRP20170712T1 (hr) | 2010-04-02 | 2017-07-28 | Ogeda Sa | Novi spojevi selektivnih antagonista nk-3 receptora, farmaceutski pripravak i postupci za uporabu kod poremećaja uzrokovanih nk-3 receptorima |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| TWI627167B (zh) | 2011-07-08 | 2018-06-21 | 諾華公司 | 用於高三酸甘油酯個體治療動脈粥狀硬化之方法 |
| CA2849751C (en) | 2011-10-03 | 2019-06-11 | Euroscreen Sa | Chiral n-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptormediated disorders and chiral synthesis thereof |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| WO2014126979A1 (en) | 2013-02-14 | 2014-08-21 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
| CA2918074A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
| CA2918077A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
| NZ730295A (en) | 2014-09-25 | 2023-05-26 | Ogeda Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
| AU2016209968B2 (en) | 2015-01-23 | 2018-11-29 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| KR102708936B1 (ko) | 2015-11-20 | 2024-09-25 | 포르마 세라퓨틱스 인크. | 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| CA3095367A1 (en) | 2018-03-29 | 2019-10-03 | Board Of Regents, The University Of Texas System | Imidazopiperazine inhibitors of transcription activating proteins |
| WO2019195846A1 (en) * | 2018-04-06 | 2019-10-10 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| WO2020110011A1 (en) | 2018-11-27 | 2020-06-04 | Novartis Ag | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3582315A (en) * | 1968-03-22 | 1971-06-01 | Lilly Co Eli | Methods and compositions for inhibiting plant growth |
| US4617307A (en) * | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US6150347A (en) * | 1992-04-21 | 2000-11-21 | The Curators Of The University Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
| DE4237656A1 (de) * | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| JPH07101959A (ja) | 1993-09-30 | 1995-04-18 | Sankyo Co Ltd | １−メチルカルバペネム誘導体 |
| DE4341453A1 (de) * | 1993-12-06 | 1995-06-08 | Merck Patent Gmbh | Imidazopyridine |
| AU6015796A (en) | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
| US20050014939A1 (en) * | 1999-08-31 | 2005-01-20 | Neurogen Corporation | Fused pyrrolecarboxamides: GABA brain receptor ligands |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
-
2003
- 2003-08-06 JP JP2004526900A patent/JP4533139B2/ja not_active Expired - Fee Related
- 2003-08-06 DE DE60307483T patent/DE60307483T2/de not_active Expired - Lifetime
- 2003-08-06 EP EP03784194A patent/EP1537114B8/en not_active Expired - Lifetime
- 2003-08-06 US US10/523,870 patent/US7732603B2/en not_active Expired - Fee Related
- 2003-08-06 CN CNB038238780A patent/CN100404535C/zh not_active Expired - Lifetime
- 2003-08-06 PT PT03784194T patent/PT1537114E/pt unknown
- 2003-08-06 WO PCT/EP2003/008720 patent/WO2004014914A1/en not_active Ceased
- 2003-08-06 ES ES03784194T patent/ES2270143T3/es not_active Expired - Lifetime
- 2003-08-06 AT AT03784194T patent/ATE335744T1/de not_active IP Right Cessation
- 2003-08-06 AU AU2003253387A patent/AU2003253387A1/en not_active Abandoned
- 2003-08-06 CA CA002494636A patent/CA2494636A1/en not_active Abandoned
- 2003-08-06 BR BR0313293-5A patent/BR0313293A/pt not_active IP Right Cessation
- 2003-08-06 DK DK03784194T patent/DK1537114T3/da active
-
2006
- 2006-10-24 CY CY20061101527T patent/CY1106217T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7732603B2 (en) | 2010-06-08 |
| CN100404535C (zh) | 2008-07-23 |
| DE60307483T2 (de) | 2007-07-05 |
| EP1537114B8 (en) | 2007-10-03 |
| WO2004014914A1 (en) | 2004-02-19 |
| EP1537114B1 (en) | 2006-08-09 |
| CN1688583A (zh) | 2005-10-26 |
| JP4533139B2 (ja) | 2010-09-01 |
| ATE335744T1 (de) | 2006-09-15 |
| HK1080290A1 (en) | 2006-04-21 |
| EP1537114A1 (en) | 2005-06-08 |
| CY1106217T1 (el) | 2011-06-08 |
| JP2006505520A (ja) | 2006-02-16 |
| AU2003253387A1 (en) | 2004-02-25 |
| US20060166973A1 (en) | 2006-07-27 |
| ES2270143T3 (es) | 2007-04-01 |
| DK1537114T3 (da) | 2006-11-13 |
| DE60307483D1 (de) | 2006-09-21 |
| CA2494636A1 (en) | 2004-02-19 |
| PT1537114E (pt) | 2006-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0313293A (pt) | Compostos orgânicos | |
| BR0316306A (pt) | Compostos orgânicos | |
| WO2008076336A3 (en) | Imidazoles as aldosterone synthase inhibitors | |
| WO2004032846A3 (en) | Triazolone and triazolethione derivatives | |
| AR040017A1 (es) | Combinacion de compuestos organicos | |
| MA27431A1 (fr) | Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques | |
| NO20051788L (no) | Hydantoinderivater og deres anvendelse som TACE-inhibitorer | |
| UY25321A1 (es) | Combinaciones de inhibidor de ace-inhibidor de mmp | |
| NO20010446L (no) | Substituert anilidforbindelser og metoder | |
| TR200103216T2 (tr) | Pirimidinon bileşimleri | |
| EP1497435A4 (en) | STEM CELLS DERIVED FROM PLAZENTA AND THEIR USES | |
| DZ3402A1 (fr) | Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement | |
| NZ595196A (en) | Peptide-based compounds for enzyme inhibition | |
| WO2004020410A3 (en) | Dihydropyridinone derivatives as hne inhibitors | |
| NO20050514L (no) | Sammensetning og antiviral aktivitet til substituerte azaindoloksoeddikpiperazinderivater | |
| AU7548500A (en) | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents | |
| BR0316196A (pt) | Diidrofenantridinasulfonamidas substituìdas | |
| ATE483708T1 (de) | Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase | |
| EA200100951A1 (ru) | Комбинированная терапия ингибитором ангиотензинпревращающего фермента и эпоксистероидным антагонистом альдостерона для лечения сердечно-сосудистого заболевания | |
| NO20060247L (no) | Substituerte spirobenzazepiner | |
| ES2181897T3 (es) | Composicion enzimatica. | |
| BRPI0611674A2 (pt) | compostos quÍmicos | |
| MY120255A (en) | 1-(4-arylpiperazin-1-yl)-hertz-[n-(alpha, hertz-dicarboximido)]-alkanes useful as uro-selective (alpha1)-adrenoceptor blockers | |
| NO20042138L (no) | Forbindelser og fremgangsmate for behandling av hyperaktiv blaere | |
| DK1214323T3 (da) | Indoloazepiner som vasopressinreceptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2157 DE 08/05/2012. |